Blueprint
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of report
(Date of earliest event reported): November 13, 2019
|
|
ENDRA
Life Sciences Inc.
|
|
|
|
(Exact name of
registrant as specified in its charter)
|
|
|
|
Delaware
|
|
001-37969
|
|
26-0579295
|
|
|
|
(State or other
jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
3600
Green Court, Suite 350, Ann Arbor, MI
|
|
48105
|
|
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
|
(Registrant’s
telephone number, including area code): (734) 335-0468
Not
Applicable
(Former name or
former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General
Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.0001 per share
|
NDRA
|
The Nasdaq Stock Market LLC
|
|
Warrants, each to purchase one share of Common Stock
|
NDRAW
|
The Nasdaq Stock Market LLC
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth
company ☑
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
Condition
On November 13,
2019, ENDRA Life Sciences Inc. issued a press release announcing
its financial results for the quarter ended September 30, 2019. A
copy of the press release is being furnished as Exhibit 99.1 to
this Current Report on Form 8-K.
The
information in Item 2.02 of this Current Report on Form 8-K and
Exhibit 99.1 attached hereto is intended to be furnished and shall
not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or
otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
The
following exhibit is furnished herewith:
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
|
Press Release dated
November 13, 2019.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
ENDRA
Life Sciences Inc.
|
|
Date: November 13,
2019
|
By:
|
/s/ Francois
Michelon
|
|
|
Name:
|
Francois
Michelon
|
|
|
Title:
|
Chief Executive
Officer and Director
|